Drug
UV1
UV1 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
unknown125%
recruiting125%
completed250%
Recent Activity
1 active trials
Showing 4 of 4
completedphase_2
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT04382664
completedphase_1
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
NCT03538314
recruitingphase_2
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
NCT05344209
unknownphase_2
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
NCT05075122
Clinical Trials (4)
Showing 4 of 4 trials
NCT04382664Phase 2
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
NCT03538314Phase 1
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
NCT05344209Phase 2
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
NCT05075122Phase 2
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4